Drug Profile

ARRY 502

Alternative Names: ARRY502

Latest Information Update: 02 Aug 2019

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Array BioPharma
Class Antiallergics
Mechanism of Action Prostaglandin D2 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Asthma

Highest Development Phases

Suspended Allergic asthma

Most Recent Events

30 Jul 2019 Array Biopharma has been acquired by Pfizer
17 Oct 2014 Suspended - Phase-II for Allergic asthma in USA (PO)
03 Mar 2014 Efficacy and adverse events data from a phase IIa trial in Allergic asthma presented at the American Academy of Allergy, Asthma and Immunology (AAAAI-2014)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com